Jpmorgan Chase & CO Champions Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Champions Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11 shares of CSBR stock, worth $46. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11
Previous 11
-0.0%
Holding current value
$46
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CSBR
# of Institutions
25Shares Held
5.82MCall Options Held
0Put Options Held
15K-
Battery Management Corp. Boston, MA2.42MShares$10.3 Million3.63% of portfolio
-
Nea Management Company, LLC Timonium, MD1.71MShares$7.32 Million0.64% of portfolio
-
Tocqueville Asset Management L.P. New York, NY705KShares$3.01 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA307KShares$1.31 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny120KShares$512,3610.0% of portfolio
About CHAMPIONS ONCOLOGY, INC.
- Ticker CSBR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,522,400
- Market Cap $57.7M
- Description
- Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...